CG Oncology, Inc. Common stock
NASDAQ:CGONBiotechnology
+$1.35 today
- Market cap
- $7.15B
- Beta
- 0.31
- P/E (TTM)
- -28.0
- EPS (TTM)
- -$2.21
Volume 1.79M
Average 1.08M
CGON EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
CG Oncology, Inc. Common stockNASDAQ: CGON
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$55.74M, compared with -$43.39M a year earlier. Trailing-twelve-month EBITDA was -$233.76M.
Context
- EBITDA amounted to 3949.3% of revenue in FY2025, down 3777.4 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of -$234.28M (-46.8%) for the fiscal year ending Dec 2026, a step up from the -81.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$55.74M+28.7% QoQ
- Last fiscal yearDec 2025
- -$159.55M-81.3% YoY
- LTMSep 2026
- -$233.76M-54.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -28.4% | -55.5% | -27.0 pp |
| 1 year | -81.3% | -46.8% | +34.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (159.55M) USD
- Year-over-year change
- -81.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (159.55M) | -81.3% |
| FY2024 | 2024-12-31 | (88.01M) | -81.1% |
| FY2023 | 2023-12-31 | (48.59M) | -37.2% |
| FY2022 | 2022-12-31 | (35.43M) | -186.2% |
| FY2021 | 2021-12-31 | (12.38M) | — |
EBITDA vs competitors
How CGON compares with its peers on the latest reported figures
- CGON's LTM Sep 2026 EBITDA of -$233.76M is the 2nd highest of the 3 companies compared; the peer median is -$560.69M.
- Its year-over-year change of -54.9% is the 2nd highest of 3, against a peer median of -168.9%.
- EBITDA amounts to 3791.2% of revenue for CGON, versus a peer median of 316.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$115.78M | -5.5% | — | 82.4% | |
| LTM Sep 2026 | -$233.76M | -54.9% | — | 3791.2% | |
| LTM Sep 2026 | -$1.01B | -332.3% | — | 550.8% | |
| Peer median (excluding CGON) | -$560.69M | -168.9% | — | 316.6% | |
Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.36M | 191K | 204K | 1.14M | 4.04M |
| Cost of Revenue | 10K | 15K | 45.75M | 82.1M | 4.65M |
| Gross Profit | 10.35M | 176K | (45.55M) | (80.96M) | (607K) |
| Gross Margin | 99.9% | 92.1% | -22327.5% | -7108.3% | -15.0% |
| Research & Development | 18.32M | 29.03M | 45.75M | 82.1M | 116.64M |
| Selling, General & Admin | 4.64M | 6.39M | 9.9M | 33.7M | 73.53M |
| Operating Expenses | 22.95M | 35.42M | 9.9M | 33.7M | 190.17M |
| Depreciation & Amortization | 10K | 15K | 17K | 32K | 1.45M |
| EBITDA | (12.38M) | (35.43M) | (48.59M) | (88.01M) | (159.55M) |
| EBITDA Margin | -119.5% | -18548.2% | -23818.6% | -7726.7% | -3949.3% |
| Operating Income | (12.61M) | (35.25M) | (55.45M) | (114.67M) | (190.77M) |
| Operating Margin | -121.7% | -18453.4% | -27180.9% | -10067.3% | -4722.1% |
| Interest Income | 0 | 0 | 6.9M | 26.62M | 29.93M |
| Interest Expense | 451K | 1K | 0 | 0 | 0 |
| Other Income / Expenses | (233K) | (197K) | 6.84M | 26.63M | 29.78M |
| Income Before Tax | (12.84M) | (35.44M) | (48.61M) | (88.04M) | (161M) |
| Pre-Tax Margin | -124.0% | -18556.5% | -23827.0% | -7729.5% | -3985.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.84M) | (35.44M) | (48.61M) | (88.04M) | (161M) |
| Net Margin | -124.0% | -18556.5% | -23827.0% | -7729.5% | -3985.0% |
| EPS (Basic) | (0.28) | (0.66) | (1.02) | (1.41) | (2.08) |
| EPS (Diluted) | (0.28) | (0.66) | (1.02) | (1.41) | (2.08) |
| Weighted Avg Shares | 66.64M | 66.64M | 66.64M | 62.5M | 77.3M |
| Weighted Avg Shares (Diluted) | 66.64M | 66.64M | 66.64M | 62.5M | 77.3M |
CG Oncology, Inc. Common stock
NASDAQ:CGON
Intrinsic Alpha fair value
Locked
Current Price
$80.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.